[go: up one dir, main page]

TN2011000366A1 - Use of deferiprone for treatment and prevention of iron-related eye dosorders - Google Patents

Use of deferiprone for treatment and prevention of iron-related eye dosorders

Info

Publication number
TN2011000366A1
TN2011000366A1 TN2011000366A TN2011000366A TN2011000366A1 TN 2011000366 A1 TN2011000366 A1 TN 2011000366A1 TN 2011000366 A TN2011000366 A TN 2011000366A TN 2011000366 A TN2011000366 A TN 2011000366A TN 2011000366 A1 TN2011000366 A1 TN 2011000366A1
Authority
TN
Tunisia
Prior art keywords
iron
deferiprone
eye
treatment
prevention
Prior art date
Application number
TN2011000366A
Other languages
English (en)
Inventor
Michael Spino
Joshua Lawrence Dunaief
Original Assignee
Joshua Lawrence Dunaief
Michael Spino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joshua Lawrence Dunaief, Michael Spino filed Critical Joshua Lawrence Dunaief
Publication of TN2011000366A1 publication Critical patent/TN2011000366A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000366A 2009-01-26 2011-07-26 Use of deferiprone for treatment and prevention of iron-related eye dosorders TN2011000366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14724509P 2009-01-26 2009-01-26
PCT/CA2009/001639 WO2010083582A1 (fr) 2009-01-26 2009-11-12 Utilisation de défériprone pour le traitement et la prévention de troubles oculaires liés au fer

Publications (1)

Publication Number Publication Date
TN2011000366A1 true TN2011000366A1 (en) 2013-03-27

Family

ID=42355449

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000366A TN2011000366A1 (en) 2009-01-26 2011-07-26 Use of deferiprone for treatment and prevention of iron-related eye dosorders

Country Status (24)

Country Link
US (1) US20130023569A1 (fr)
EP (1) EP2389179A4 (fr)
JP (1) JP5604631B2 (fr)
KR (1) KR20120078667A (fr)
CN (1) CN102348456A (fr)
AP (1) AP2011005843A0 (fr)
AU (1) AU2009338093B2 (fr)
BR (1) BRPI0920492A2 (fr)
CA (1) CA2750599A1 (fr)
CL (1) CL2011001812A1 (fr)
CR (1) CR20110456A (fr)
EA (1) EA201170970A1 (fr)
IL (1) IL214291A (fr)
MA (1) MA33090B1 (fr)
MX (1) MX2011007947A (fr)
MY (1) MY161269A (fr)
NI (1) NI201100148A (fr)
NZ (1) NZ594728A (fr)
PE (1) PE20120515A1 (fr)
SG (1) SG173145A1 (fr)
TN (1) TN2011000366A1 (fr)
UA (1) UA103366C2 (fr)
WO (1) WO2010083582A1 (fr)
ZA (1) ZA201105514B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016205030B2 (en) * 2015-01-09 2021-04-01 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
NZ787785A (en) 2017-10-25 2025-11-28 Chiesi Farm S P A Delayed release deferiprone tablets and methods of using the same
US12016850B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone
US12016851B2 (en) 2022-04-11 2024-06-25 Chiesi Farmaceutici S.P.A. Modified release pharmaceutical formulations comprising deferiprone

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5674888A (en) * 1995-06-07 1997-10-07 University Of California Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
AUPQ262499A0 (en) * 1999-09-02 1999-09-23 University Of Queensland, The Novel iron chelators
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
EP1601367A2 (fr) * 2003-02-06 2005-12-07 Bioresponse L.L.C. Utilisation combinee d'indoles cruciferes et de chelateurs pour le traitement d'etats lies au papillomavirus
RU2008137604A (ru) * 2006-02-22 2010-03-27 Арнольд МЮННИК (FR) Применение деферипрона и способ лечения и/или профилактики атаксии фридрейха, возникающей вследствие внутриклеточного нарушения обмена железа
EP2012789B1 (fr) 2006-04-14 2013-09-25 Prana Biotechnology Limited Procédé de traitement de la dégénérescence maculaire liée a l'âge (DMA)
ITMI20061770A1 (it) * 2006-09-18 2008-03-19 Carlo Ghisalberti Metodo cosmetico di riduzione delle occhiaie
US8501789B2 (en) * 2007-01-19 2013-08-06 The Trustees Of The University Of Pennsylvania Use of salicylaldehyde isonicotinoyl hydrazone (SIH) for protection against retinal disease

Also Published As

Publication number Publication date
CA2750599A1 (fr) 2010-07-29
AP2011005843A0 (en) 2011-08-31
UA103366C2 (ru) 2013-10-10
JP2012515725A (ja) 2012-07-12
AU2009338093A1 (en) 2011-09-08
IL214291A0 (en) 2011-09-27
SG173145A1 (en) 2011-08-29
WO2010083582A1 (fr) 2010-07-29
US20130023569A1 (en) 2013-01-24
EA201170970A1 (ru) 2012-03-30
JP5604631B2 (ja) 2014-10-08
MY161269A (en) 2017-04-14
CR20110456A (es) 2012-05-31
MA33090B1 (fr) 2012-03-01
MX2011007947A (es) 2011-12-14
CN102348456A (zh) 2012-02-08
NI201100148A (es) 2012-03-06
CL2011001812A1 (es) 2012-02-03
IL214291A (en) 2015-03-31
PE20120515A1 (es) 2012-05-20
AU2009338093B2 (en) 2014-08-28
NZ594728A (en) 2013-03-28
EP2389179A4 (fr) 2012-08-29
ZA201105514B (en) 2012-10-31
BRPI0920492A2 (pt) 2019-07-09
EP2389179A1 (fr) 2011-11-30
KR20120078667A (ko) 2012-07-10

Similar Documents

Publication Publication Date Title
WO2011113013A3 (fr) Procédés et compositions pour le traitement d'états viraux ou induits par des virus
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
BR112015012312A2 (pt) método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011085162A3 (fr) Compositions topiques transdermiques de dexmédétomidine et leurs procédés d'utilisation
WO2013180834A3 (fr) Compositions et procédés d'inhibition de masp-1 et/ou masp-3 pour le traitement l'hémoglobinurie paroxysmique nocturne
NZ600874A (en) Fluorinated derivatives of deferiprone
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
NZ594365A (en) Dual targeting of miR-208a or miR-208b and miR-499 in the treatment of cardiac disorders or musculoskeletal disorders
NZ586302A (en) Pre-surgical treatment using brimonidine applied topically to reduce bleeding or bruising
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2014071168A3 (fr) Administration d'inhibiteurs de la signalisation tgfbêta, dérivés de benzothiazépine ou combinaisons de ceux-ci pour améliorer la fonction musculaire chez des patients cancéreux
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2010030976A3 (fr) Procédés et compositions destinés à inhiber l'athérosclérose et une inflammation vasculaire
CA2866819C (fr) Procede de traitement de l'inflammation
WO2015061777A3 (fr) Traitement de l'urticaire chronique idiopathique, de l'anaphylaxie et de l'œdème de quincke
UA106131C2 (uk) Засіб для профілактики і лікування захворювань, які супроводжуються болем в органах сечовипускання
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
MX2010011193A (es) Composicion farmaceutica liquida para el tratamiento y prevencion del dolor.
WO2009088849A3 (fr) Traitement ou prévention d'inflammation par ciblage de cycline d1
PH12015501538A1 (en) Topical ocular analgesic agents